凤凰网财经《IPO观察哨》 近日，王俊凯代言的植物医生以"4500家门店、1400万会员"的亮眼数据高调启动上市计划，不过，凤凰 网财经《IPO观察哨》发现，植物医生背后却暗藏内控漏洞、业绩停滞与研发投入等多重隐忧。 报告期内，公司及子公司累计收到16张行政处罚单，涉及虚假宣传、供应链监管不力等问题；与此同 时，营收增速近乎停滞，远落后于同行，经销渠道持续萎缩。 更令人质疑的是，公司虽宣称"重研发"，但研发人员两年缩减超20%，核心技术依赖委外，而营销费用 却高达研发支出的10倍以上。 此外，植物医生在IPO前进行了上亿元的分红，公司董事长谢勇控制79.14%的股权是此次分红的最大受 益者。 植物医生董事长谢勇 这些矛盾与风险，为植物医生的上市之路蒙上了一层阴影。 01 全资公司三年16罚 内控漏洞集中暴露 植物医生的上市之路充满波折。2023年7月，公司携"4500家门店、1400万会员"的高调数据启动A股IPO 辅导，成为国内首个冲击资本市场的单品牌美妆企业。 然而这场资本征程在起点便遭遇阻碍，原本计划的IPO辅导期被迫延长19个月，直到2025年6月底才获 得深交所受理。据报道，辅导机构中信证券在报告中 ...

当数字技术重塑海洋治理，当智能工具重构资源开发，海洋计算正成为解锁海洋经济潜能的"新钥匙"。 在国家高度重视海洋经济发展、力推海洋科技创新的大背景下，海洋计算作为融合前沿科技与海洋产业的关键领域，其战略意义愈发凸显。海洋计算挑战 赛(MCC)正是这一趋势的缩影——通过"产学研"深度协同，将实验室技术转化为可落地的产业价值，为海洋强国建设注入新动能。 赋能新质生产力发展 "挑战源于前沿难题，平台承载未来突破" 由中国太平洋学会于2024年创办的海洋计算挑战赛(Marine Computing Challenge，简称MCC)，今年迎来第二届。 紧密围绕海洋计算科学开展，以海洋数值模式高性能计算优化为主线，针对海洋应用领域中的技术痛点与难点展开深入探讨。以"产学研融合"为内核，为 青年科技人才搭建从理论突破到产业落地的全链条平台。 国家战略引领下的海洋使命 "国家所需，就是计算所向" 近年来，国家持续强调海洋经济对国民经济增长的重要支撑作用，出台系列政策鼓励海洋科技创新。 从《全国海洋经济发展"十四五"规划》，到对海洋高端装备、海洋信息科技等领域的重点扶持，无不彰显国家对海洋产业升级的决心。 海洋计算作为新兴交叉 ...

Core Viewpoint - Recently, Buchang Pharma (603858.SH) announced that its subsidiary, Zhejiang Tianyuan Biopharmaceutical Co., Ltd., has received the drug registration certificate for the quadrivalent influenza virus split vaccine from the National Medical Products Administration, making it the 9th certified company for this vaccine in China [1] Group 1: Vaccine Approval and Market Potential - The quadrivalent influenza vaccine is a key step in Buchang Pharma's strategy to expand from traditional Chinese medicine into biopharmaceuticals and vaccines [1] - Research indicates that approximately 84 million to 144 million people in China contract influenza annually, highlighting the significant market potential for vaccination [1] - The current vaccination rate for influenza in China is low, indicating substantial room for growth [1] Group 2: Timing and Production Advantages - The approval of the vaccine is timely, as the peak influenza season occurs from November to March, and vaccination requires 2-4 weeks to develop protective antibodies [1] - The vaccine was approved in July, allowing ample time for production and market distribution to meet the upcoming vaccination peak [1] Group 3: Product Details - The quadrivalent influenza virus split vaccine contains 15μg of each type of influenza virus hemagglutinin per 0.5ml dose, and is classified as a prescription biological product [3][4] - The vaccine is manufactured by Zhejiang Tianyuan Biopharmaceutical Co., Ltd., located in Hangzhou, Zhejiang Province [3][4] Group 4: R&D Investment and Commitment - As of June 30, 2025, Buchang Pharma has invested approximately 126 million yuan in the vaccine project, reflecting its commitment to new drug development [7] - The company emphasizes strict quality control throughout the drug development, manufacturing, and sales processes, showcasing its technical capabilities [7] Group 5: Shareholder Returns and Corporate Responsibility - Buchang Pharma has consistently returned value to shareholders through cash dividends and share buybacks, having paid out a total of 9.183 billion yuan since its listing [8] - The company plans to reduce its registered capital by repurchasing 44.8536 million shares, which is expected to enhance per-share value and stabilize stock prices [8] - Buchang Pharma has contributed over 32 billion yuan in taxes since its establishment, demonstrating its commitment to social responsibility and local economic development [8]

7月15日，汽车零部件巨头法雷奥中国首席技术官顾剑民在"2025新能源智能汽车新质发展论坛"上表 示，"中国创造，服务全球"代表了法雷奥在华发展战略，中国是全球汽车的"健身房"。他提到，中国的 研发效率、研发团队的能力在全球领先。例如在中国，法雷奥团队开发一个智能大灯产品只要8-10个 月，这些产品的开发效率，在欧洲和美国目前还做不到，同样的产品在欧美的开发周期基本上要两年左 右。中国也有非常强大的制造能力，尤其是自动化生产的能力。例如其深圳工厂今年年初被评为全球灯 塔工厂，全球灯塔工厂在全球不足200家，法雷奥深圳工厂是整个集团的第一家灯塔工厂。(智通财经) ...

Core Viewpoint - Bluefan Medical (002382.SZ) is expected to narrow its net loss in the first half of 2025 to between 1 billion and 1.5 billion yuan, with a reduction of 6.38% compared to the previous period, driven by the growth of new products and a significant increase in sales revenue from its cardiovascular division [1] Group 1: Financial Performance - The company anticipates a sales revenue exceeding 690 million yuan from its cardiovascular division in the first half of 2025, representing a year-on-year growth of over 20% [1] - The company reported a fair value loss of approximately 120 million yuan due to the valuation changes of its investment in Suzhou Tongxin Medical Technology Co., Ltd., which does not involve cash outflow [1] - Financial expenses of 25 million yuan were incurred in the second quarter of 2025 due to strategic investment matters related to its subsidiary, which also does not involve cash outflow [1] Group 2: Business Strategy and Innovation - Since entering the high-end medical device sector through the acquisition of Bosheng International in 2018, Bluefan Medical has shifted its focus from low-value consumables to high-value consumables, with over 2 billion yuan invested in R&D [2] - The company has been recognized in the field of innovative medical devices, particularly in the area of intravascular shockwave (IVL) technology, which is crucial for treating calcified vascular lesions [2] - Bluefan Medical has developed proprietary electrode technology that operates at lower voltages while achieving higher acoustic pressure, enhancing treatment efficacy compared to similar products [3] Group 3: Market Expansion - The company plans to leverage its existing overseas teams, channels, and stable customer relationships to expand its market presence, focusing on regions where local registration qualifications can be accepted [3] - Future plans include conducting larger-scale post-market clinical studies to lead the operational concepts and standardized treatment guidelines for IVL in the global market [3]

Group 1 - The core viewpoint of the article emphasizes the importance of after-sales service in establishing brand trust and market presence, particularly for Agilent [2] - A user satisfaction survey is being conducted to gather feedback on Agilent's after-sales service, aiming to identify strengths and weaknesses for service improvement [2] - The survey is open to all Agilent users and will run until July 25, 2025, with participants having the chance to win a phone credit reward [2] Group 2 - The survey aims to cover a wide range of Agilent's instrument products to ensure comprehensive feedback collection [2] - Participants who complete the survey will receive a reward of 30 yuan, with a total of 200 rewards available on a first-come, first-served basis [2]

在华研发战略转型，正在给合资车企带来新的活力。 大众汽车在华开发增程式车型，宝马深度融合鸿蒙生态，丰田、通用等将产品研发主导权交由中国团队……不仅如此，德国汽车工业协会对70家会员企 业（覆盖整车、Tier1及中小企业）的调研显示，尽管2024年跨国车企及零部件企业在华利润普遍下滑，但几乎所有企业仍保持正向利润。 "在所调研的企业中，有近70％明确计划在2025年及以后加大对华投资，其中超过78％的企业将投资重点聚焦于研发领域。"德国汽车工业协会（中国） 首席代表兼总经理张琳表示，跨国汽车企业在华合作已进入以"研发2.0"为核心的合资合作2.0时代。 这一战略转型，让合资车企迎来新的机遇。中国电动汽车百人会副理事长兼秘书长张永伟表示："当前，跨国车企正在加速由技术研发和供应链'两头在 外'（在中国生产，技术研发和供应商在海外）的发展模式，向'在中国 为世界'的新本土化模式转变。" 加码长期研发投入 从曾经在华市场份额占比70％到不足31％，合资品牌正面临新的挑战。正因如此，迫使合资车企深入思考在中国市场如何破局。 进入新能源汽车时代，数十年前自主品牌学习、对标合资品牌的情况，正在反转。"追赶'中国速度'是跨国 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future investment returns [4][6]. Core Views - The company is expected to face significant pressure on its performance in the first half of 2025, with projected net profit declining by 88.24% to 91.98% year-on-year, primarily due to tax payments by its subsidiary and weak downstream demand in the clean energy sector [1][2]. - Despite the challenges in the clean energy business, the semiconductor display materials segment is anticipated to continue its growth trajectory, contributing positively to the company's overall performance [3][4]. Summary by Relevant Sections Performance Forecast - For 2025, the company forecasts a net profit of 7.6 million to 22 million yuan, with a significant year-on-year decline [1]. - The clean energy business has been adversely affected by low downstream demand and tax payments totaling 166 million yuan, impacting the net profit by approximately 132 million yuan [2]. Semiconductor Display Materials - The semiconductor display materials business, particularly liquid crystal products, has achieved record sales and profitability, with a compound annual growth rate (CAGR) of 12.2% in revenue and 17.1% in gross profit from 2020 to 2024 [3]. - The company is focusing on enhancing its competitive edge through technology innovation and has become a leading supplier in the TN/STN and TFT-LCD mixed liquid crystal materials market [3]. Profitability and Valuation - The report projects a downward adjustment in profit forecasts for 2025 to 2027, with expected net profits of 7.6 million, 15.4 million, and 18.5 million yuan respectively [4]. - The earnings per share (EPS) for these years are estimated at 0.06, 0.13, and 0.15 yuan [4][5].

近日，中国科学院上海光学精密机械研究所杨帆研究员牵头成功研制了国际首台高时空分辨受激布里渊 显微镜，在保持优异成像质量和高频谱特异性的前提下，将成像速度提升两个数量级，首次在国际上实 现了亚毫秒时间分辨与亚微米空间分辨的三维力学成像，为生命科学中的力学研究提供了重要工具。相 关成果近日在国际学术期刊《自然·光子学》（Nature Photonics）发表。（央视新闻） ...

Core Viewpoint - The leading global collaborative robot company, Yujian Technology, announced a significant financing plan to raise over HKD 1 billion through a discounted share placement to accelerate technology research and global market expansion [1][2]. Financing Plan - Yujian plans to issue 19.1 million new H-shares at a price of HKD 54.3 per share, representing a discount of approximately 9.5% from the last closing price of HKD 60 [1]. - The share placement will dilute the existing share capital by about 4.73%, with a projected net fundraising amount of approximately HKD 1.022 billion after expenses [1]. Strategic Focus - The raised funds will be allocated to four strategic areas: increasing investment in core technology research, seeking opportunities for industry chain integration, expanding global sales channels, and supporting operational funding for emerging application scenarios [1][2]. Financial Performance - For 2024, Yujian reported a revenue of HKD 374 million, a year-on-year increase of 30.3%, but still recorded a net loss of HKD 103 million [2]. - The adjusted loss narrowed significantly by 55.4%, with a gross margin improvement to 46.6% [2]. Product and Market Position - Yujian's core product, the six-axis collaborative robot, contributed 55.9% of total revenue, with a strong year-on-year growth of 55.5% [2]. - The company has a self-research rate of over 90% for key components and has accumulated 961 patents [2]. Market Expansion - Yujian's products are currently available in over 80 countries and regions, serving more than 80 Fortune 500 companies, with overseas revenue accounting for 59% [3]. - The capital injection is expected to enhance competitiveness against international giants in terms of R&D speed, production capacity, and market coverage [3]. Market Reaction - Following the announcement, Yujian's stock price fell by 2.67% to HKD 58.4, but has seen a cumulative increase of 146.41% this year [3][4]. - Analysts believe that while the discounted placement may cause short-term stock volatility, the funding is likely to accelerate the company's path to profitability [3]. Challenges Ahead - Yujian faces ongoing profitability pressures, with R&D expenses reaching HKD 77.52 million in 2024, necessitating broader scale applications to dilute high costs [3]. - The economic viability of new commercial service robots will be crucial for large-scale market adoption [3].